Bulk Raw Materials Rivaroxaban Powder

CAS:366789-02-8

MF:C19H18ClN3O5S

MW:435.88 

EINECS:685-132-2

Specification: 99% min Rivaroxaban Powder

Sample: Rivaroxaban Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Rivaroxaban Powder Usage and Synthesis.

Novel anticoagulants were first used for thromboprophylaxis after orthopaedic surgeries, including total hip and knee replacements, and have been reported to be non-inferior to low molecular heparin in terms of efficacy and safety.

Nowadays, new anticoagulants are gradually being widely used in the treatment of lower limb venous thrombosis and pulmonary embolism. The latest ESC guideline for the diagnosis and treatment of acute pulmonary embolism in 2014 mentions that new anticoagulants can be used as an emerging anticoagulant to replace traditional anticoagulant treatments, which will also be gradually promoted in cardiovascular diseases of high incidence, such as atrial fibrillation and acute coronary syndromes.

Uses and functions of Rivaroxaban.

Rivaroxaban, is approved for use in adult patients undergoing hip or knee replacement surgery to prevent venous thrombosis (VTE); and for the treatment of deep vein thrombosis (DVT) in adults to reduce the risk of DVT recurrence and pulmonary embolism (PE) following acute DVT.

Atrial fibrillation (AF) is a common cardiac arrhythmia with a prevalence of up to 10 per cent in people over the age of 75. In patients with AF, blood tends to stagnate in the atria and form blood clots, the dislodgement of which can lead to stroke.

Rivaroxaban, is approved and recommended for adult patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism.

For use in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis.

Pharmacological Effects of Rivaroxaban.

Rivaroxaban is a highly selective and competitive inhibitor of free and bound factor Xa and prothrombin activity, prolonging activated partial thromboplastin time (PT) and aPTT in a dose-dependent manner.

Rivaroxaban is essentially different from sodium sulfadoxine/heparin in that it does not require the involvement of antithrombin III, antagonises free and bound factor Xa to reduce thrombin activation and thus prolongs the clotting time, and not only blocks the formation of clots, but also destroys clots that have already formed.

Rivaroxaban helps to prevent the formation and further development of blood clots during hip or knee replacements, when the backflow of blood from the leg veins to the heart is poor and blood clots are easily formed.

Usage and dosage of Rivaroxaban Powder.

Rivaroxaban dosage may vary between dosage forms and sizes, please read the specific drug instructions for use or follow your doctor's advice.

Rivaroxaban Tablets:

1、The recommended dose is oral rivaroxaban 10mg once daily.

2, If the wound has stopped bleeding, the first dose should be administered between 6-10 hours after surgery.

3, The length of the treatment course is based on each patient's risk of venous thromboembolic events, i.e. by the type of orthopaedic surgery the patient has undergone (see instructions for details). For patients undergoing major hip surgery, the recommended course of treatment is 5 weeks. For patients undergoing major knee surgery, the recommended course of treatment is 2 weeks. In the event of a missed dose, patients should take rivaroxaban immediately and continue to take a daily dose the following day. Patients may take rivaroxaban with a meal or alone.